Q BioMed Inc
Change company Symbol lookup
Select an option...
QBIO Q BioMed Inc
LCSHY Lancashire Holdings Ltd
NET Cloudflare Inc
PRCT PROCEPT BioRobotics Corp
AAL American Airlines Group Inc
ATXS Astria Therapeutics Inc
FRGT Freight Technologies Inc
ABNB Airbnb Inc
BNMV BitNile Metaverse Inc
CNTA Centessa Pharmaceuticals PLC

Health Care : Biotechnology |
Company profile

Q BioMed, Inc. is a biomedical acceleration and development company. The Company focuses on licensing, acquiring and providing strategic resources to life sciences and healthcare companies. Q BioMed acquires assets across healthcare related products, companies and sectors. It has portfolio of five therapeutic products, including Strontium-89 and MetastronTM for metastatic bone cancer pain and three development stage products: QBM-001 for rare pediatric non-verbal autism spectrum disorder; Uttroside-B for liver cancer, and MAN 01 for glaucoma. Its MAN platform has therapeutics in development in various indications, including vascular and infectious diseases. It holds license for a generic drug, Strontium Chloride (SR89). SR89 is a radiopharmaceutical agent and indicated for the treatment of bone cancer. The infectious diseases that it can treat includes influenza, COVID-19, Ebola and others. The Company's subsidiaries include Q BioMed Cayman SEZC and QBMG Q BioMed Germany UG.

Closing Price
Day's Change
-0.0003 (-2.18%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

The risk of loss in trading futures can be substantial. Clients must consider all relevant risk factors, including their own personal financial situation, before trading. Margin and level 2 options approval or higher is required. Not all account owners will qualify.

Dividends are converted to USD using the current rate of exchange at the end of the business day on the day the dividend went EX. Earnings are converted to USD using the current rate of exchange at the end of the business day on the day earnings were announced.

Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.